Replies to post #126198 on Biotech Values

[DewDiligence]

The critique of the Xarelto ROCKET-AF study is valid on strictly statistical grounds, as we had previously noted on this board (e.g. #msg-56717469). Nevertheless, I don’t for a minute believe that “skillful” use of warfarin is better for AF patients than Xarelto. This is an instance of a bad pivotal trial, not a bad drug (echoing what Dr. Pazdur once said about Erbitux).